(Reuters Health) - When the U.S. Food and Drug Administration announced in 2009 that Pfizer Inc’s smoking-cessation drug Chantix would need to carry a restrictive “black box” warning label, the move didn’t really surprise the market. The drug’s sales had already been declining. By the end of 2009, they had dropped to $700 million, down from $846 million the previous year.
